Seattle – October 13, 2016 – Cooley advised Aquinox Pharmaceuticals on its $75.4 million public offering of 6,152,500 shares of common stock.
Aquinox, which trades on The NASDAQ Global Market as AQXP, is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology.
Cooley advised Aquinox on its IPO in 2014 and its follow-on offering in 2015.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.